• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Vyvanse for Sluggish Cognitive Tempo in ADHD
RESEARCH UPDATE

Vyvanse for Sluggish Cognitive Tempo in ADHD

August 1, 2022
Thomas Jordan, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Thomas Jordan, MD. Dr. Jordan, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Adler LA et al, J Clin Psychiatry 2021;82(4):20m13687

STUDY TYPE: Randomized placebo-controlled trial

Patients with ADHD often also struggle with sluggish cognitive tempo (SCT). Characteristics of SCT include being prone to daydreaming, being easily bored, feeling “spacey” or lethargic, and not processing information quickly or accurately. This diagnosis—which is not found in the DSM—is controversial, and it has the most support when it occurs as a comorbidity of ADHD.

Studies of methylphenidate and atomoxetine have shown some improvement in SCT among youth with ADHD. This industry-sponsored study, which used lisdexamfetamine (Vyvanse), is the first stimulant trial for SCT in adults.

The investigators recruited 39 adults with comorbid ADHD and SCT. This was a “clean” cohort, meaning that no one had another active psychiatric disorder and no one had a lifetime history of bipolar disorder. The trial used a crossover design, in which all patients received either stimulant or placebo over a four-week treatment block, then everyone underwent a two-week washout period before switching to the other group in a second four-week treatment block. Lisdexamfetamine was started at 30 mg daily and titrated up to 70 mg daily.

The dual primary outcomes were changes in the ADHD Rating Scale and the Barkley Sluggish Cognitive Tempo Scale. In the first treatment block, lisdexamfetamine had a medium effect size (0.68) for SCT, but the stimulant had only a nonsignificant effect during the second block, possibly due to a carryover effect. When the subjects on lisdexamfetamine were switched to placebo for the second block, their average ratings for SCT did not revert to baseline, suggesting that lisdexamfetamine’s benefits may have carried over after the switch. Alternatively, the findings in the first block may have been a false positive.

Unlike the changes in SCT, subjects’ ADHD ratings showed improvements in both four-week treatment periods with lisdexamfetamine (all p = <0.05), including measures of executive functioning and functional impairment.

Side effects were what we would expect from lisdexamfetamine: decreased appetite (11%), headache (10%), and anxiety (4%). There were no serious adverse events, and only one participant withdrew due to side effects (anxiety).

CARLAT TAKE

Patients with SCT and ADHD can expect to see improvement with amphetamine-based stimulants like lisdexamfetamine. SCT by itself is not an accepted diagnosis, and we should take caution to avoid overdiagnosis.


General Psychiatry Research Update
KEYWORDS cognition side effects vyvanse
    Thomas Jordan, MD

    Do Psychosocial Interventions Improve Quality of Life in Advanced Dementia?

    More from this author
    www.thecarlatreport.com
    Issue Date: August 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Complementary Therapy in ADHD
    What Gets in the Way of Antidepressants?
    Six Tips From Prescribing Psychotropics
    Vyvanse for Sluggish Cognitive Tempo in ADHD
    Does Vitamin B6 Prevent Postpartum Depression?
    CME Post-Test - ADHD, TCPR, August 2022
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.